BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug ...

Kavita Nair, PhD, discusses integrating neurology and pharmacy services to improve MS care coordination and reduce treatment delays.

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...

If approved, Zenas will enter the RMS market, which is currently dominated by anti-CD20 antibodies like Roche’s Ocrevus.

RIVERSIDE, N.J. (WPVI) -- A multiple sclerosis diagnosis used to mean a future of disability. But now, a revolution in medications allows MS patients to pursue their dreams. Those medications are ...

About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.

Tolebrutinib delayed disability progression by 31% in people with secondary progressive multiple sclerosis No drugs are currently approved to treat this type of MS WEDNESDAY, April 9, 2025 (HealthDay ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...

As an FDA advisory panel meets Wednesday to vote on whether to recommend approval of Sanofi’s MS drug Lemtrada, patient opinion leaders have already voiced their view. A small majority told ...

MS patients with Medicare plans that exclude more drugs have a higher risk of relapse They might not be able to afford the drugs that would work best for them TUESDAY, Aug. 5, 2025 (HealthDay News) — ...